ATE520979T1 - Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors - Google Patents

Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors

Info

Publication number
ATE520979T1
ATE520979T1 AT06813702T AT06813702T ATE520979T1 AT E520979 T1 ATE520979 T1 AT E520979T1 AT 06813702 T AT06813702 T AT 06813702T AT 06813702 T AT06813702 T AT 06813702T AT E520979 T1 ATE520979 T1 AT E520979T1
Authority
AT
Austria
Prior art keywords
biomarrkers
egf
modulators
receptor
methods
Prior art date
Application number
AT06813702T
Other languages
English (en)
Inventor
Shirin K Ford
Edwin A Clark
Xin Huang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE520979T1 publication Critical patent/ATE520979T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06813702T 2005-08-24 2006-08-24 Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors ATE520979T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71105405P 2005-08-24 2005-08-24
PCT/US2006/033073 WO2007025044A2 (en) 2005-08-24 2006-08-24 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Publications (1)

Publication Number Publication Date
ATE520979T1 true ATE520979T1 (de) 2011-09-15

Family

ID=37772388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06813702T ATE520979T1 (de) 2005-08-24 2006-08-24 Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors

Country Status (7)

Country Link
US (2) US8129114B2 (de)
EP (1) EP1917528B1 (de)
JP (1) JP2009505658A (de)
AT (1) ATE520979T1 (de)
CA (1) CA2620195A1 (de)
ES (1) ES2370054T3 (de)
WO (1) WO2007025044A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
EP2527460B1 (de) 2004-05-27 2014-12-24 The Regents of The University of Colorado Verfahren zur Vorhersage der klinischen Resultate in Bezug auf epidermale Wachstumsfaktor-Rezeptorhemmer von Krebspatienten
DK2465950T3 (en) 2007-03-13 2017-10-09 Amgen Inc K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY TREATMENT
AU2016250348A1 (en) * 2007-03-13 2016-11-10 Amgen Inc. K-ras mutations and anti-EGFr antibody therapy field
US8975081B2 (en) 2007-10-24 2015-03-10 Faron Pharmaceuticals Oy Biomarker for monitoring development of diseases and assessing the efficacy of therapies
FI20070795A0 (fi) * 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy
US8273534B2 (en) 2008-05-14 2012-09-25 Genomic Health, Inc. Predictors of patient response to treatment with EGF receptor inhibitors
WO2010065626A1 (en) * 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
US20110269139A1 (en) * 2009-01-06 2011-11-03 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
BRPI1015179A2 (pt) * 2009-06-19 2016-04-19 Merck Patent Gmbh biomarcadores e métodos para a determinação de eficácia de anticorpos anti-egfr em terapia de câncer
MY165154A (en) * 2009-08-24 2018-02-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
EP2507628A4 (de) * 2009-12-01 2013-04-24 Medimmune Llc Verbesserte verfahren und zusammensetzungen für den nachweis und die behandlung von cea-exprimierenden tumoren
NZ602920A (en) * 2010-04-12 2014-07-25 Response Genetics Inc Kras primers and probes
MX385227B (es) 2012-01-20 2025-03-14 Del Mar Pharmaceuticals Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y análogos para tratar enfermedad neoplásica y células madre de cáncer que incluyen glioblastoma multiforme y meduloblastoma.
EP2823307A4 (de) * 2012-03-08 2015-07-29 Bioscale Inc Verfahren und kits zur analyse von biomarkern in einem signaltransduktionsweg
US20150293105A1 (en) * 2012-10-26 2015-10-15 The University Of Queensland Methods for classifying tumors and uses therefor
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CN104762371B (zh) 2014-01-07 2021-03-09 三星电子株式会社 用于预测或监控c-Met抑制剂效力的生物标志物
US20150254433A1 (en) * 2014-03-05 2015-09-10 Bruce MACHER Methods and Models for Determining Likelihood of Cancer Drug Treatment Success Utilizing Predictor Biomarkers, and Methods of Diagnosing and Treating Cancer Using the Biomarkers
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
US20160024585A1 (en) * 2014-05-02 2016-01-28 Duke University Methods of predicting responsiveness of a cancer to an agent and methods of determining a prognosis for a cancer patient
KR20160037666A (ko) 2014-09-29 2016-04-06 삼성전자주식회사 KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측
EP3073268A1 (de) 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker-tafel zur diagnose von krebs
CN108474040B (zh) * 2015-10-09 2023-05-16 夸登特健康公司 使用无细胞dna的基于群体的治疗推荐
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
CN109457052A (zh) * 2018-12-18 2019-03-12 苏州德思普生物科技有限公司 检测人类免疫缺陷病毒核酸的引物、探针、试剂盒及检测方法
EP4217393A1 (de) * 2020-09-22 2023-08-02 Ventana Medical Systems, Inc. Vorhersage der reaktion auf epidermalen wachstumsfaktorrezeptorgerichtete therapien mit epiregulin und amphiregulin
CN117964690B (zh) * 2024-02-04 2024-07-23 北京榕树堂生物科技有限公司 一种具有保护皮肤弹性及抗炎功效的燕窝肽ⅲ及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6713619B1 (en) * 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5591582A (en) * 1985-07-23 1997-01-07 The Board Of Rijks Universiteit Leiden Methods for detecting activated RAS oncogenes
WO1991016051A1 (en) 1990-04-16 1991-10-31 Rhône-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
SK281143B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5656655A (en) * 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
AU1441497A (en) 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6156504A (en) * 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
EP0907642B1 (de) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
HUP0103520A3 (en) 1998-09-29 2003-01-28 Wyeth Holdings Corp Madison Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
AU2001247616B2 (en) * 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
DK2258872T3 (da) * 2002-03-13 2013-11-18 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
JP2007520995A (ja) 2003-01-08 2007-08-02 ブリストル−マイヤーズ　スクイブ　カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
AU2004291709C1 (en) 2003-05-30 2010-03-11 Astrazeneca Uk Limited Process
EP1759010A4 (de) * 2004-01-07 2008-12-24 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
CA2561111A1 (en) 2004-03-26 2005-10-13 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
EP3042964A1 (de) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr-mutationen
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
EP1913157B2 (de) * 2005-06-28 2016-10-26 Genentech, Inc. Egfr- und kras-mutationen zur vorhersage der reaktion eines patienten auf egfr-hemmer-behandlung
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7858389B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
EP2412828B1 (de) * 2007-03-13 2013-06-05 Amgen Inc. K-RAS- und B-BAF-Mutationen und anti-EGFR-Antikörpertherapie
DK2465950T3 (en) * 2007-03-13 2017-10-09 Amgen Inc K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY TREATMENT

Also Published As

Publication number Publication date
JP2009505658A (ja) 2009-02-12
ES2370054T3 (es) 2011-12-12
US8129114B2 (en) 2012-03-06
WO2007025044A2 (en) 2007-03-01
US20120195889A1 (en) 2012-08-02
WO2007025044A8 (en) 2007-07-05
CA2620195A1 (en) 2007-03-01
EP1917528A4 (de) 2009-03-11
WO2007025044A3 (en) 2007-09-20
EP1917528B1 (de) 2011-08-17
EP1917528A2 (de) 2008-05-07
US20100221754A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
WO2007025044A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2004063709A8 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2005094332A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
WO2010006048A3 (en) Gene expression profiling for predicting the survivability of prostate cancer subjects
DE60332639D1 (de) Verwendung von biomarkern zum nachweis von eierstockkrebs
WO2008144345A3 (en) Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
MX2010003438A (es) Sistema capilar con elemento fluidico.
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2008063414A3 (en) Gene expression profiling for identification, monitoring, and treatment of colorectal cancer
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE523777T1 (de) System und verfahren zur bestimmung der analytkonzentration mittels zeitaufgelöster amperometrie
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2005067667A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
DE60021369D1 (de) Verfahren zur abschätzung eines magengeschwür-risikos
DK2185937T4 (da) Fremgangsmåde til at bestemme sepsis hos mennesker
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
DE602006021038D1 (de) Verfahren zur diagnose eines ovarialkarzinoms
ATE476527T1 (de) Quantifizierungsverfahren für die vegf isoformen einer biologischen probe
ATE543914T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
ATE528651T1 (de) Diagnoseverfahren für pulmonale arterielle hypertonie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties